IRLAB Therapeutics AB Class A (0GFH) Share Price & Analysis
0GFH Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- SEK 310.81M
- Enterprise Value
- SEK 95.31M
- Total Cash (Recent Filing)
- SEK 34.22M
- Total Debt (Recent Filing)
- SEK 24.20M
- Price to Earnings (P/E)
- ―
- Beta
- 0.00
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet
Leverage has improved materially from prior years, reducing balance-sheet risk and providing greater financial flexibility. The roughly 97M equity base offers some cushion while IRLAB continues funding clinical development, although persistent losses could gradually weaken that support.
Narrowing Losses
The reduction in losses indicates that IRLAB is moving toward a more efficient cost and revenue profile, even though it remains unprofitable. If this trend persists, it could extend the company’s runway and improve its ability to fund development before commercial revenues emerge.
Focused CNS Pipeline Model
A focused clinical-stage strategy in CNS disorders gives IRLAB a clear therapeutic identity and concentrates resources on Parkinson’s-related unmet needs. Its collaboration model can also create future milestone, funding, and royalty opportunities if candidates advance successfully.
Bears Say
Deep Unprofitability
Deep losses and a shrinking top line show that the current business has not yet reached the scale needed to cover its cost base. Continued unprofitability can consume capital, limit development choices, and make future progress dependent on successful pipeline advancement.
Persistent Cash Burn
Negative operating and free cash flow means ongoing research and development are not being funded by internal operations. This reduces financial resilience and increases the importance of achieving sustainable revenue or securing additional funding as programs move through development.
External Funding Dependence
Reliance on external financing leaves IRLAB exposed to the need for repeated capital raising while its products remain in development. Equity funding can dilute existing holders, and uncertain collaboration income makes the timing of self-sustaining operations difficult to predict.
IRLAB Therapeutics AB Class A News
0GFH FAQ
What is IRLAB Therapeutics AB Class A’s market cap?
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
Is IRLAB Therapeutics AB Class A overvalued?
Does IRLAB Therapeutics AB Class A pay dividends?
What is IRLAB Therapeutics AB Class A’s EPS estimate?
How many shares outstanding does IRLAB Therapeutics AB Class A have?
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
What is the TipRanks Smart Score and how is it calculated?
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kristina Torfgard
- Employees
- 31
- Website
- www.irlab.se
- Address
- Arvid Wallgrens Backe 20, Gothenburg, VG, 413 46, SE
